Augmentation strategies in obsessive–compulsive disorder
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Around 40-60% of patients with obsessive-compulsive disorder do not show adequate response to selective serotonin reuptake inhibitors (SSRIs). Augmentation strategies are recommended in people who show partial response to SSRI treatment or poor response to multiple SSRIs. In this article, the authors review the evidence for augmentation strategies. The available evidence is predominantly based on small-scale, randomized controlled trials, open-label trials and case series. Antipsychotic augmentation, especially risperidone, haloperidol, aripiprazole and cognitive-behavior therapy have shown the best evidence. Ondansetron, memantine, riluzole, clomipramine, mirtazapine and repetitive transcranial magnetic stimulation over supplementary motor area show some preliminary evidence. Ablative neurosurgery or deep brain stimulation may be tried in carefully selected treatment refractory patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Foa, E. B., Liebowitz, M. R., Kozak, M. J., Davies, S., Campeas, R., Franklin, M. E., Huppert, J. D., Kjernisted, K., Rowan, V., Schmidt, A. B., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.151 · Cited by 1,048
Bloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V, Bracken, M. B., & Leckman, J. F. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001823 · Cited by 635
McDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571 · cited 1×
“McDougle et al. (1994) Haloperidol; 6.2 (3.0) A = 17; P = 17 4 Fluvoxamine 8 weeks 26 A: 64.7% vs P: 0%‡ Haloperidol > placebo [27] McDougle et al. (2000) Risperidone; 2.2 ± 0.7 A = 20; P = 16 6 Any SSRI 12 weeks 31.8 A: 50% vs P: 0%‡,§ Risperidone > placebo [29] Hollander et al. (2003)…”
InfluentialPsychological treatment of obsessive–compulsive disorder: A meta-analysis
Rosa-Alcázar, A. I., Sánchez-Meca, J., Gómez-Conesa, A., & Marín-Martínez, F. (2008) · Clinical Psychology Review · doi:10.1016/j.cpr.2008.07.001 · Cited by 444
Pittenger, C., Bloch, M. H., & Williams, K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.006 · Cited by 426
Treatment non-response in OCD: methodological issues and operational definitions
Pallanti, S., Hollander, E., Bienstock, C., Koran, L., Leckman, J., Marazziti, D., Pato, M., Stein, D., Zohar, J., & International Treatment Refractory OCD Consortium (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702002900 · Cited by 416
Invasive circuitry-based neurotherapeutics: stereotactic ablation and deep brain stimulation for OCD
Greenberg, B. D., Rauch, S. L., & Haber, S. N. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.128 · Cited by 359
Simpson, H. B., Foa, E. B., Liebowitz, M. R., Ledley, D. R., Huppert, J. D., Cahill, S., Vermes, D., Schmidt, A. B., Hembree, E., Franklin, M., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07091440 · Cited by 316 · cited 1×
“…ERP§ Therapist group: 7.5 weeks; self-group: 6 weeks 41 patients on adequate medication trial Therapist administered ERP > self-administered ERP [103] Simpson et al. (2008) ERP vs stress management training + SSRI 17 twice-weekly sessions 108 OCD patients on SSRI trial ERP > stress…”
MethodInfluentialRiluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial
Coric, V., Taskiran, S., Pittenger, C., Wasylink, S., Mathalon, D. H., Valentine, G., Saksa, J., Wu, Y.-T., Gueorguieva, R., Sanacora, G., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.043 · Cited by 314
Neurosurgery for intractable obsessive-compulsive disorder and depression: critical issues
Greenberg, B. D., Price, L. H., Rauch, S. L., Friehs, G., Noren, G., Malone, D., Carpenter, L. L., Rezai, A. R., & Rasmussen, S. A. (2003) · Neurosurgery Clinics of North America · doi:10.1016/s1042-3680(03)00005-6 · Cited by 300
Mantovani, A., Simpson, H. B., Fallon, B. A., Rossi, S., & Lisanby, S. H. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990435 · Cited by 281 · cited 1×
“…management plus instruction in CBT vs medication management plus CBT 12 weeks 124 OCD patients (7–17 years) on SSRI trial CBT was more effective [105] Mantovani et al. (2010) Low frequency rTMS over SMA/ sham rTMS + SSRI 4 weeks double blind 21 medication-resistant patients Active rTMS…”
MethodFranklin, M. E., Sapyta, J., Freeman, J. B., Khanna, M., Compton, S., Almirall, D., Moore, P., Choate-Summers, M., Garcia, A., Edson, A. L., et al. (2011) · JAMA · doi:10.1001/jama.2011.1344 · Cited by 278 · cited 1×
“…[103] Simpson et al. (2008) ERP vs stress management training + SSRI 17 twice-weekly sessions 108 OCD patients on SSRI trial ERP > stress management [104] Franklin et al. (2011) Medication management alone vs medication management plus instruction in CBT vs medication management plus CBT 12…”
MethodMarek, G. J., Carpenter, L. L., McDougle, C. J., & Price, L. H. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300057 · Cited by 275
Denys, D., de Geus, F., van Megen, H. J. G. M., & Westenberg, H. G. M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0803 · Cited by 248
Bystritsky, A., Ackerman, D. L., Rosen, R. M., Vapnik, T., Gorbis, E., Maidment, K. M., & Saxena, S. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0418 · Cited by 220
Saxena, S., Brody, A. L., Ho, M. L., Zohrabi, N., Maidment, K. M., & Baxter, L. R. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.3.522 · Cited by 210
Hollander, E., Rossi, N. B., Sood, E., & Pallanti, S. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003730 · Cited by 197 · cited 1×
“…> placebo [27] McDougle et al. (2000) Risperidone; 2.2 ± 0.7 A = 20; P = 16 6 Any SSRI 12 weeks 31.8 A: 50% vs P: 0%‡,§ Risperidone > placebo [29] Hollander et al. (2003) Risperidone; 2.25 (0.86) A = 10; P = 6 8 Any SSRI 12 weeks 19.04 A: 40% vs P: 0%¶ Risperidone > placebo [38] Erzegovesi…”
InfluentialGrant, P., Lougee, L., Hirschtritt, M., & Swedo, S. E. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0021 · Cited by 197
A Single-Blinded Case-Control Study of Memantine in Severe Obsessive-Compulsive Disorder
Stewart, S. E., Jenike, E. A., Hezel, D. M., Stack, D. E., Dodman, N. H., Shuster, L., & Jenike, M. A. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c856de · Cited by 158
Bourne, S. K., Eckhardt, C. A., Sheth, S. A., & Eskandar, E. N. (2012) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2012.00029 · Cited by 146
Carey, P. D., Vythilingum, B., Seedat, S., Muller, J. E., van Ameringen, M., & Stein, D. J. (2005) · BMC Psychiatry · doi:10.1186/1471-244x-5-5 · Cited by 133 · cited 11×
“…A: 64.4% vs P: 0%‡ Quetiapine > placebo [46] Denys et al. (2004) Quetiapine; 300 A = 20; P = 20 8 Any SSRI 8 weeks 31 A: 40% vs P: 20%‡ Quetiapine > placebo [43] Carey et al. (2005) Quetiapine; 168.75 (120.82) A = 20; P = 21 6 Any SSRI 12 weeks 17.75 A: 40% vs P: 47.6%§ Quetiapine = placebo…”
InfluentialClomipramine, Clonazepam, and Clonidine Treatment of Obsessive-Compulsive Disorder
HEWLETT, W. A., VINOGRADOV, S., & AGRAS, W. S. (1992) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199212000-00008 · Cited by 129
Muscatello, M. R. A., Bruno, A., Pandolfo, G., Micò, U., Scimeca, G., Romeo, V. M., Santoro, V., Settineri, S., Spina, E., & Zoccali, R. A. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31820e3db6 · Cited by 122 · cited 11×
“…A: 27% vs P:10%§ Quetiapine = placebo [44] Kordon et al. (2008) Quetiapine; 400–600 A = 20; P = 20 12 Any SSRI 12 weeks 22 A: 65% vs P: 44%‡ Quetiapine = placebo [45] Muscatello et al. (2011) Aripiprazole; 15 A = 16; P = 14¶ 16 Any SSRI 8 weeks 28.5 A: 25%‡ Aripiprazole > placebo [54] Sayyah et…”
InfluentialSerotoninergic mechanisms in the treatment of obsessive–compulsive disorder
Goddard, A. W., Shekhar, A., Whiteman, A. F., & McDougle, C. J. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.12.009 · Cited by 112
Li, X., May, R. S., Tolbert, L. C., Jackson, W. T., Flournoy, J. M., & Baxter, L. R. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0610 · Cited by 110
Matsunaga, H., Nagata, T., Hayashida, K., Ohya, K., Kiriike, N., & Stein, D. J. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04369 · Cited by 110
Sayyah, M., Sayyah, M., Boostani, H., Ghaffari, S. M., & Hoseini, A. (2012) · Depression and Anxiety · doi:10.1002/da.21996 · Cited by 105 · cited 5×
“Aripiprazole and haloperidol are the next options.”
InfluentialFineberg, N. A., Sivakumaran, T., Roberts, A., & Gale, T. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200507000-00005 · Cited by 105 · cited 11×
“69 Diniz JB, Shavitt RG, Pereira CA et al. Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive–compulsive disorder: a randomized, open-label trial.”
InfluentialTreatment of Obsessive-Compulsive Disorder by U.S. Psychiatrists
Blanco, C., Olfson, M., Stein, D. J., Simpson, H. B., Gameroff, M. J., & Narrow, W. H. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0611 · Cited by 103
A double-blind, placebo-controlled trial of clonazepam in obsessive–compulsive disorder
Hollander, E., Kaplan, A., & Stahl, S. M. (2003) · The World Journal of Biological Psychiatry · doi:10.3109/15622970309167908 · Cited by 97 · cited 1×
“…> placebo [27] McDougle et al. (2000) Risperidone; 2.2 ± 0.7 A = 20; P = 16 6 Any SSRI 12 weeks 31.8 A: 50% vs P: 0%‡,§ Risperidone > placebo [29] Hollander et al. (2003) Risperidone; 2.25 (0.86) A = 10; P = 6 8 Any SSRI 12 weeks 19.04 A: 40% vs P: 0%¶ Risperidone > placebo [38] Erzegovesi…”
InfluentialAdjunctive glycine in the treatment of obsessive-compulsive disorder in adults
Greenberg, W. M., Benedict, M. M., Doerfer, J., Perrin, M., Panek, L., Cleveland, W. L., & Javitt, D. C. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.10.007 · Cited by 80
Koran, L. M., Aboujaoude, E., & Gamel, N. N. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04605 · Cited by 79 · cited 1×
“…(2009) Glycine (60 mg/day) vs placebo + SSRI 12 weeks 14 OCD patients on stabilized treatment Glycine nonsignificant improvement – poor tolerability [90] Koran et al. (2009) d-amphetamine 30 mg/day vs caffeine 300 mg/day + SSRI/SNRI 5 weeks 24 OCD patients with adequate trial of SSRI/ SNRI Both…”
BackgroundAnand, N., Sudhir, P. M., Math, S. B., Thennarasu, K., & Janardhan Reddy, Y. C. (2011) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2011.05.007 · Cited by 65
Marazziti, D., Pfanner, C., Dell’osso, B., Ciapparelli, A., Presta, S., Corretti, G., Di Nasso, E., Mungai, F., & Dell’osso, L. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105053299 · Cited by 56
Cited by
Clinical practice guidelines for Obsessive-Compulsive Disorder
Janardhan Reddy, Y., Sundar, A., Narayanaswamy, J., & Math, S. (2017) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.196976 · Cited by 156
Hadi, F., Kashefinejad, S., Kamalzadeh, L., Hoobehfekr, S., & Shalbafan, M. (2021) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-021-00534-6 · Cited by 36
Treatment Resistance in Obsessive-Compulsive Disorder
Middleton, R., Wheaton, M. G., Kayser, R., & Simpson, H. B. (2019) · Treatment Resistance in Psychiatry · doi:10.1007/978-981-10-4358-1_11 · Cited by 19
Metadata
- Authors
- Arumugham, S. S., & Reddy, J. Y.
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2013-02
- Volume
- 13
- Issue
- 2
- Pages
- 187-203
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W1997161535
- Cited by
- 75
- References
- 35
- FWCI
- 9.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.